GlycoMimetics Inc (NAS:GLYC)
$ 0.3131 -0.0079 (-2.46%) Market Cap: 20.19 Mil Enterprise Value: 6.06 Mil PE Ratio: 0 PB Ratio: 1.78 GF Score: 30/100

GlycoMimetics Inc at Stifel Virtual Healthcare Conference Transcript

Nov 17, 2020 / 01:00PM GMT
Release Date Price: $4.02 (+6.63%)
Operator

My name is Ellen Sands, and I'm a biotechnology associate at Stifel. And today, I have the pleasure of speaking with Rachel King, the CEO of GlycoMimetics. (Operator Instructions)

So Rachel, thanks for being here today, and...

Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director

Sure.

Ellen Sands
Stifel, Nicolaus & Company, Incorporated, Research Division - Research Analyst

And maybe to start, you can give a brief overview of GlycoMimetics and just touch on the pipeline at a high level, and then we can dive in after that.

Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director

Sure. So we're a clinical stage company. We've got a late-stage program now in AML, which is in 2 Phase III registration trials, one is treating newly diagnosed patients who are fit for chemotherapy, and the other treating relapsed/refractory patients also fit for chemotherapy. That's our most advanced program.

We also have a program that recently

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot